leflunomide has been researched along with Blood Pressure, High in 10 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide is effective and well tolerated in the treatment of rheumatoid arthritis (RA), however, data on its use in early RA are scarce." | 9.14 | Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. ( Bornholdt, K; Hein, G; Kellner, H, 2010) |
| "To study the safety and efficacy of infliximab plus leflunomide combination therapy in adult rheumatoid arthritis (RA)." | 9.10 | Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. ( Johnson, DM; Kiely, PD, 2002) |
| " She was known to have type 1 diabetes mellitus, previous Hashimoto's thyroiditis, rheumatoid arthritis treated with leflunomide and drug- treated arterial hypertension." | 7.74 | [Persistent diarrhea and loss of weight during therapy with leflunomide]. ( Berges, W; Donner, P; Gugenberger, C; Naami, A, 2008) |
| "To determine the frequency of new-onset hypertension in patients with Rheumatoid arthritis taking leflunomide, in comparison with methotrexate in Asian setting." | 5.30 | Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg. ( Ishaq, M; Kumar, A; Muhammad, JS; Razzaque, S; Shohail, F, 2019) |
| "Leflunomide is effective and well tolerated in the treatment of rheumatoid arthritis (RA), however, data on its use in early RA are scarce." | 5.14 | Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. ( Bornholdt, K; Hein, G; Kellner, H, 2010) |
| "To study the safety and efficacy of infliximab plus leflunomide combination therapy in adult rheumatoid arthritis (RA)." | 5.10 | Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. ( Johnson, DM; Kiely, PD, 2002) |
| " Mycophenolate and leflunomide are teratogenic drugs and should be withdrawn before conception in case of programmed pregnancy or should be rapidly discontinued in case of unexpected pregnancy." | 4.91 | Immunosuppression in pregnant women with systemic lupus erythematosus. ( Moroni, G; Ponticelli, C, 2015) |
| " Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1." | 3.88 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC, 2018) |
| " She was known to have type 1 diabetes mellitus, previous Hashimoto's thyroiditis, rheumatoid arthritis treated with leflunomide and drug- treated arterial hypertension." | 3.74 | [Persistent diarrhea and loss of weight during therapy with leflunomide]. ( Berges, W; Donner, P; Gugenberger, C; Naami, A, 2008) |
| "Treatment with leflunomide or low doses of glucocorticoids were not associated with severe course in our cohort." | 2.82 | COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia. ( Hočevar, A; Ješe, R; Kramarič, J; Rotar, Ž; Tomšič, M, 2022) |
| "Patients with treated hypertension should be monitored regularly when conventional NSAIDs or COX-2 inhibitors are administered." | 2.41 | Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. ( Dijkmans, BA; Nurmohamed, MT; van Halm, VP, 2002) |
| "Gender, age, and hypertension are associated with KD recurrence." | 1.43 | Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients. ( Chen, Y; Liu, Z; Wang, J; Xu, F; Zeng, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kramarič, J | 1 |
| Ješe, R | 1 |
| Tomšič, M | 2 |
| Rotar, Ž | 1 |
| Hočevar, A | 1 |
| Ishaq, M | 1 |
| Razzaque, S | 1 |
| Shohail, F | 1 |
| Kumar, A | 1 |
| Muhammad, JS | 1 |
| Baker, JF | 1 |
| Sauer, B | 1 |
| Teng, CC | 1 |
| George, M | 1 |
| Cannon, GW | 1 |
| Ibrahim, S | 1 |
| Cannella, A | 1 |
| England, BR | 1 |
| Michaud, K | 1 |
| Caplan, L | 1 |
| Davis, LA | 1 |
| OʼDell, J | 1 |
| Mikuls, TR | 1 |
| Ponticelli, C | 1 |
| Moroni, G | 1 |
| Chen, Y | 1 |
| Wang, J | 1 |
| Xu, F | 1 |
| Zeng, C | 1 |
| Liu, Z | 1 |
| Gugenberger, C | 1 |
| Donner, P | 1 |
| Naami, A | 1 |
| Berges, W | 1 |
| Kellner, H | 1 |
| Bornholdt, K | 1 |
| Hein, G | 1 |
| Nurmohamed, MT | 1 |
| van Halm, VP | 1 |
| Dijkmans, BA | 1 |
| Rozman, B | 1 |
| Praprotnik, S | 1 |
| Logar, D | 1 |
| Hojnik, M | 1 |
| Kos-Golja, M | 1 |
| Accetto, R | 1 |
| Dolenc, P | 1 |
| Kiely, PD | 1 |
| Johnson, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Secondary Event Prevention Using Population Risk Management After PCI[NCT02694185] | 5,269 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. (NCT02694185)
Timeframe: 1 year
| Intervention | Cardiovascular events (Mean) |
|---|---|
| Experimental Group | 15.2 |
| Control Group | 14.3 |
To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. (NCT02694185)
Timeframe: through study completion, an average of 1 year
| Intervention | dollars per patient (Median) |
|---|---|
| Experimental Group | 821.45 |
| Control Group | 893.55 |
Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. (NCT02694185)
Timeframe: 1 year
| Intervention | percentage of days covered (Mean) | ||
|---|---|---|---|
| Anti-platelet | Beta-Blocker | Statin | |
| Control Group | 75.6 | 73.3 | 71.2 |
| Experimental Group | 82.6 | 78.4 | 78.8 |
3 reviews available for leflunomide and Blood Pressure, High
| Article | Year |
|---|---|
COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.
Topics: Cardiovascular Diseases; COVID-19; Giant Cell Arteritis; Glucocorticoids; Humans; Hypertension; Lefl | 2022 |
Immunosuppression in pregnant women with systemic lupus erythematosus.
Topics: Contraindications; Cyclosporine; Female; Glucocorticoids; Humans; Hypertension; Immunosuppression Th | 2015 |
Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular | 2002 |
3 trials available for leflunomide and Blood Pressure, High
| Article | Year |
|---|---|
Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg.
Topics: Adult; Arthritis, Rheumatoid; Asian People; Case-Control Studies; Female; Humans; Hypertension; Immu | 2019 |
Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Sedimentation; Di | 2010 |
Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.
Topics: Adult; Aged; Anaphylaxis; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoa | 2002 |
4 other studies available for leflunomide and Blood Pressure, High
| Article | Year |
|---|---|
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; | 2018 |
Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients.
Topics: Adolescent; Adult; Angiolymphoid Hyperplasia with Eosinophilia; Anti-Inflammatory Agents; China; Fem | 2016 |
[Persistent diarrhea and loss of weight during therapy with leflunomide].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Colitis, Lymphocytic; Diabetes Mellitus, Type 1; Diarrh | 2008 |
Leflunomide and hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Hypertension; Isoxazoles; Le | 2002 |